US equities
|
MU
$913.38
▲+4.08%
TSLA
$394.15
▲+5.89%
NVDA
$216.28
▲+2.52%
SPCX
$148.72
▲+0.83%
META
$634.55
▼-1.26%
AAPL
$343.30
▼-1.27%
SNDK
$1,272.73
▲+2.80%
INTC
$91.75
▲+5.51%
MU
$913.38
▲+4.08%
TSLA
$394.15
▲+5.89%
NVDA
$216.28
▲+2.52%
SPCX
$148.72
▲+0.83%
META
$634.55
▼-1.26%
AAPL
$343.30
▼-1.27%
SNDK
$1,272.73
▲+2.80%
INTC
$91.75
▲+5.51%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
1.498
+0.408 (+37.45%)
Delayed Quote
Updated: 2:23 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
October 22, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
October 19, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
October 15, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
October 07, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
September 23, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
September 02, 2026
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing...
Via
TheNewswire.com
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
September 02, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
August 31, 2026
From
SciSparc Ltd
Via
GlobeNewswire
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
August 31, 2026
Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq:...
Via
TheNewswire.com
Neurothera Labs Inc. Announces Share Consolidation
August 28, 2026
Toronto, Ontario – August 28, 2026 –– TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),...
Via
TheNewswire.com
NeuroThera Labs Engages Dr. Reuter Investor Relations
August 27, 2026
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),...
Via
TheNewswire.com
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
August 26, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
August 18, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
August 12, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
August 05, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
July 31, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
July 29, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
July 27, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
July 15, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
June 04, 2026
From
SciSparc Ltd
Via
GlobeNewswire
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
June 03, 2026
Toronto, Ontario – June 3, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the “Company” or “NeuroThera”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd....
Via
TheNewswire.com
Topics
Intellectual Property
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
May 28, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
March 16, 2026
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
March 13, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 12, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
March 10, 2026
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 10, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc Announces 1-for-9 Reverse Share Split
March 02, 2026
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
February 02, 2026
From
SciSparc Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
